Clinical Trial Update: An Open-Label Crenezumab Study in Participants With Alzheimer's Disease [Phase 3]

View source ↗

Summary

An open-label Phase 3 trial of crenezumab in participants with Alzheimer's disease was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Crenezumab

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2020-06-09